Hormonal Contraceptive Market by Product, Hormone, Age Group, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4580665
  • Report
  • Region: Global
  • 230 pages
  • Allied Analytics LLP
1 of 4
The global hormonal contraceptive market was valued at $13,924 million in 2016, and is estimated to reach $16,018 million by 2023, registering a CAGR of 1.9% from 2017 to 2023. Hormonal contraception is a birth control method, which acts on the endocrine system, and is composed of steroid hormones. Higher concentration of naturally forming hormones such as estrogen and progesterone are used to either prevent ovulation or make unfavorable condition to develop pregnancy.

Increase in adoption of hormonal contraceptives products or birth control methods in the developing countries and incidence of polycystic ovary syndrome (PCOS) are the major driving factors for the growth of the global hormonal contraceptive market. Moreover, rise in population attaining higher education and rise in need to control the ever-growing population in developing regions such as China and India have adopted measures to prevent unwanted pregnancy, which are expected to fuel the market growth. However, availability of alternate contraceptive methods and health risks associated with the use of contraceptives hamper the market growth.

The global hormonal contraceptive market is segmented on the basis of product, hormone, age group, end user, and geography. Based on product, the market is classified into oral contraceptive pills, injectable birth control, emergency contraceptive pills, vaginal rings, and transdermal patches. Depending on hormone, it is bifurcated into progestin-only contraceptive and combined hormonal contraceptive. By age group, it is categorized into 15–24 years, 25–34 years, 35–44 years, and above 44 years. By end user, it is classified into hospitals, household, and clinics. Geographically, it is analyzed across four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product

Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Rings
Transdermal Patches

By Hormone

Progestin-only Contraceptive
Combined Hormonal Contraceptive

By Age Group

15–24 Years
25–34 Years
35–44 Years
Above 44 Years

By End User

Hospitals
Household
Clinics

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY PLAYERS PROFILED

The Female Health Company
Teva Pharmaceutical Industries Limited
Bayer AG
Pfizer, Inc.
Mylan N.V.
Johnson & Johnson
Ansell Ltd.
Mayer Laboratories
Merck & Co., Inc.
Church & Dwight, Co., Inc.

The other players of the hormonal contraceptive market include (companies not profiled in the report):

Reckitt Benckiser Plc.
Warner Chilcott Company
BioSante Pharmaceuticals Inc.
HLL Lifecare Limited
Boehringer Ingelheim GmbH
Watson Pharmaceuticals, Inc.
V-Care Pharma Pvt. Ltd.
Vardhman Life Care Pvt. Ltd.
Cipla Limited
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Top Player Positioning, 2016
3.4. Porters Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Rise in need for preventing unwanted pregnancy
3.5.1.2. Increasing awareness for contraceptives worldwide
3.5.1.3. Rising usage of oral contraceptives as a preferred method to avoid unplanned pregnancy
3.5.1.4. Technological advancements in contraceptive methods
3.5.1.5. Upsurge in government and NGO initiatives promoting contraceptives
3.5.2. Restrains
3.5.2.1. Health risks associated with the use of contraceptive methods
3.5.2.2. Lack of social acceptance
3.5.3. Opportunities
3.5.3.1. Rise in disposable income and demand for healthy life in emerging economies
3.5.3.2. Presence of large unmet contraceptive needs in emerging Asian and African economies

CHAPTER 4: HORMONAL CONTRACEPTIVE MARKET BY PRODUCT
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Oral Contraceptive Pills
4.2.1. Key market trends & growth opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country
4.3. Injectable Birth Control
4.3.1. Key market trends & growth opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country
4.4. Emergency Contraceptive Pills
4.4.1. Key market trends & growth opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country
4.5. Vaginal Rings
4.5.1. Key market trends & growth opportunities
4.5.2. Market Size and Forecast
4.5.3. Market Analysis, by Country
4.6. Transdermal Patches
4.6.1. Key market trends & growth opportunities
4.6.2. Market Size and Forecast
4.6.3. Market Analysis, by Country

CHAPTER 5: HORMONAL CONTRACEPTIVE MARKET BY HORMONE
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Progestin-only Contraceptive
5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country
5.3. Combined Hormonal Contraceptive
5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country

CHAPTER 6: HORMONAL CONTRACEPTIVE MARKET BY AGE GROUP
6.1. Overview
6.1.1. Market Size and Forecast
6.2. 15-24 years
6.2.1. Market Size and Forecast
6.2.2. Market Analysis, by Country
6.3. 25-34 years
6.3.1. Market Size and Forecast
6.3.2. Market Analysis, by Country
6.4. 35-44 years
6.4.1. Market Size and Forecast
6.4.2. Market Analysis, by Country
6.5. Above 44 years
6.5.1. Market Size and Forecast
6.5.2. Market Analysis, by Country

CHAPTER 7: HORMONAL CONTRACEPTIVE MARKET BY END USERS
7.1. Overview
7.1.1. Market Size and Forecast
7.2. Hospitals
7.2.1. Market Size and Forecast
7.2.2. Market Analysis, by Country
7.3. Household
7.3.1. Market Size and Forecast
7.3.2. Market Analysis, by Country
7.4. Clinics
7.4.1. Market Size and Forecast
7.4.2. Market Analysis, by Country

CHAPTER 8: HORMONAL CONTRACEPTIVE MARKET BY GEOGRAPHY
8.1. Overview
8.1.1. Market Size and Forecast
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, by Product Type
8.2.3. Market Size and Forecast, by Hormone
8.2.4. Market Size and Forecast, by Age Group
8.2.5. Market Size and Forecast, by End Users
8.2.6. Market Size and Forecast, by Country
8.2.6.1. U.S. Market Size and Forecast, by Product Type
8.2.6.2. U.S. Market Size and Forecast, by Hormone
8.2.6.3. U.S. Market Size and Forecast, by Age Group
8.2.6.4. U.S. Market Size and Forecast, by End Users
8.2.6.5. Canada Market Size and Forecast, by Product Type
8.2.6.6. Canada Market Size and Forecast, by Hormone
8.2.6.7. Canada Market Size and Forecast, by Age Group
8.2.6.8. Canada Market Size and Forecast, by End Users
8.2.6.9. Mexico Market Size and Forecast, by Product Type
8.2.6.10. Mexico Market Size and Forecast, by Hormone
8.2.6.11. Mexico Market Size and Forecast, by Age Group
8.2.6.12. Mexico Market Size and Forecast, by End Users
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, by Product Type
8.3.3. Market Size and Forecast, by Hormone
8.3.4. Market Size and Forecast, by Age Group
8.3.5. Market Size and Forecast, by End Users
8.3.6. Market Size and Forecast, by Country
8.3.6.1. Germany Market Size and Forecast, by Product Type
8.3.6.2. Germany Market Size and Forecast, by Hormone
8.3.6.3. Germany Market Size and Forecast, by Age Group
8.3.6.4. Germany Market Size and Forecast, by End Users
8.3.6.5. France Market Size and Forecast, by Product Type
8.3.6.6. France Market Size and Forecast, by Hormone
8.3.6.7. France Market Size and Forecast, by Age Group
8.3.6.8. France Market Size and Forecast, by End Users
8.3.6.9. UK Market Size and Forecast, by Product Type
8.3.6.10. UK Market Size and Forecast, by Hormone
8.3.6.11. UK Market Size and Forecast, by Age Group
8.3.6.12. UK Market Size and Forecast, by End Users
8.3.6.13. Italy Market Size and Forecast, by Product Type
8.3.6.14. Italy Market Size and Forecast, by Hormone
8.3.6.15. Italy Market Size and Forecast, by Age Group
8.3.6.16. Italy Market Size and Forecast, by End Users
8.3.6.17. Spain Market Size and Forecast, by Product Type
8.3.6.18. Spain Market Size and Forecast, by Hormone
8.3.6.19. Spain Market Size and Forecast, by Age Group
8.3.6.20. Spain Market Size and Forecast, by End Users
8.3.6.21. Rest of Europe Market Size and Forecast, by Product Type
8.3.6.22. Rest of Europe Market Size and Forecast, by Hormone
8.3.6.23. Rest of Europe Market Size and Forecast, by Age Group
8.3.6.24. Rest of Europe Market Size and Forecast, by End Users
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, by Product Type
8.4.3. Market Size and Forecast, by Hormone
8.4.4. Market Size and Forecast, by Age Group
8.4.5. Market Size and Forecast, by End Users
8.4.6. Market Size and Forecast, by Country
8.4.6.1. Japan Market Size and Forecast, by Product Type
8.4.6.2. Japan Market Size and Forecast, by Hormone
8.4.6.3. Japan Market Size and Forecast, by Age Group
8.4.6.4. Japan Market Size and Forecast, by End Users
8.4.6.5. China Market Size and Forecast, by Product Type
8.4.6.6. China Market Size and Forecast, by Hormone
8.4.6.7. China Market Size and Forecast, by Age Group
8.4.6.8. China Market Size and Forecast, by End Users
8.4.6.9. Australia Market Size and Forecast, by Product Type
8.4.6.10. Australia Market Size and Forecast, by Hormone
8.4.6.11. Australia Market Size and Forecast, by Age Group
8.4.6.12. Australia Market Size and Forecast, by End Users
8.4.6.13. India Market Size and Forecast, by Product Type
8.4.6.14. India Market Size and Forecast, by Hormone
8.4.6.15. India Market Size and Forecast, by Age Group
8.4.6.16. India Market Size and Forecast, by End Users
8.4.6.17. South Korea Market Size and Forecast, by Product Type
8.4.6.18. South Korea Market Size and Forecast, by Hormone
8.4.6.19. South Korea Market Size and Forecast, by Age Group
8.4.6.20. South Korea Market Size and Forecast, by End Users
8.4.6.21. Rest of Asia-Pacific Market Size and Forecast, by Product Type
8.4.6.22. Rest of Asia-Pacific Market Size and Forecast, by Hormone
8.4.6.23. Rest of Asia-Pacific Market Size and Forecast, by Age Group
8.4.6.24. Rest of Asia-Pacific Market Size and Forecast, by End Users
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, by Product Type
8.5.3. Market Size and Forecast, by Hormone
8.5.4. Market Size and Forecast, by Age Group
8.5.5. Market Size and Forecast, by End Users
8.5.6. Market Size and Forecast, by Country
8.5.6.1. Brazil Market Size and Forecast, by Product Type
8.5.6.2. Brazil Market Size and Forecast, by Hormone
8.5.6.3. Brazil Market Size and Forecast, by Age Group
8.5.6.4. Brazil Market Size and Forecast, by End Users
8.5.6.5. Saudi Arabia Market Size and Forecast, by Product Type
8.5.6.6. Saudi Arabia Market Size and Forecast, by Hormone
8.5.6.7. Saudi Arabia Market Size and Forecast, by Age Group
8.5.6.8. Saudi Arabia Market Size and Forecast, by End Users
8.5.6.9. South Africa Market Size and Forecast, by Product Type
8.5.6.10. South Africa Market Size and Forecast, by Hormone
8.5.6.11. South Africa Market Size and Forecast, by Age Group
8.5.6.12. South Africa Market Size and Forecast, by End Users
8.5.6.13. Rest of LAMEA Market Size and Forecast, by Product Type
8.5.6.14. Rest of LAMEA Market Size and Forecast, by Hormone
8.5.6.15. Rest of LAMEA Market Size and Forecast, by Age Group
8.5.6.16. Rest of LAMEA Market Size and Forecast, by End Users

CHAPTER 9: COMPANY PROFILES
9.1. Ansell Limited
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.2. Bayer AG
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments
9.3. Church & Dwight Co. Inc.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.4. Johnson & Johnson
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.5. Mayer Laboratories Inc.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.6. Merck & Co. Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.7. Mylan N.V.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments
9.8. Pfizer Inc.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments
9.10. The Female Health Company
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Hormonal Contraceptive Market by Product, Hormone, Age Group, and End Userlobal Opportunity Analysis and Industry Forecast, 2017-2023," the global hormonal contraceptive market accounted for $13,924 million in 2016, and is estimated to reach $16,018 million by 2023, registering a CAGR of 1.9% from 2017 to 2023. North America is the highest contributor in the hormonal contraceptive market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

Hormonal contraception acts on the endocrine system to prevent unwanted pregnancy. Synthetic forms of naturally occurring hormones such as progestin and estrogen are used to prevent ovulation and avoid fertilization. These forms of birth control methods also change the environment of the uterus, making it unfavorable for fertilization. Hormonal contraceptives are available in a variety of forms such as patches, pill, injection, and rings, which are safe and reliable forms of hormonal contraceptives to prevent pregnancy.

The major driving factors of the hormonal contraceptive market are increase in focus towards family planning, health issues associated with teenage pregnancies, increase in awareness about modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy. The advancement in hormonal contraception with better efficacy and fewer side effects further boost the market growth. However, availability of alternate contraceptive methods, health risks associated with the use of contraceptives, and lack of social acceptance adversely affect the market growth.

Among the product, oral contraceptive pill is the dominant segment, as these pills are easily available and have high success rate of up to 99% to prevent pregnancy. However, vaginal ring register the highest growth rate, due to the ease of usage and fewer side effects caused by it.

Combined hormonal contraceptive is the dominant segment in the hormonal contraceptive market, due to the wide availability of combined hormonal contraceptive along with better efficiency to prevent pregnancy.

In 2016, North America was the major revenue generator, owing to increase in awareness towards the benefits of using hormonal contraceptive, high prevalence of unwanted pregnancy, and favorable regulatory scenario. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, due to presence of populace countries such as India and China where there is greater need to control the growing population.

Key Findings of the Hormonal Contraceptive Market

Vaginal rings is projected to grow at the highest rate during the analysis period.
North America dominated global hormonal contraceptive market in 2016, and is projected to continue its dominance in future.
China is expected to grow at the highest rate in the Asia-Pacific region during the forecast period.
Hospitals is the largest contributor among the end user segments in 2016.
The 15-24 years age group segment generated the highest revenue, and is expected to continue its dominance in future.

The key players operating in the global hormonal contraceptive market include the Female Health Company, Teva Pharmaceutical Industries Limited, Bayer AG, Pfizer, Inc., Mylan N.V., Johnson & Johnson, Ansell LTD., Mayer Laboratories, Merck & Co., Inc., and Church & Dwight, Co., Inc.

Other prominent players in the value chain include Reckitt Benckiser Plc., Warner Chilcott Company, BioSante Pharmaceuticals Inc., HLL Lifecare Limited, Boehringer Ingelheim GmbH, Watson Pharmaceuticals, Inc., V-Care Pharma Pvt. Ltd., Vardhman Life Care Pvt. Ltd., Cipla Limited, and others.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll